Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome:
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity
Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid taper (patient one: sat unassisted for first time in over a decade, normalized sleep, stabilized seizures; patient two: improved hand stereotypies and breathing, seizure-free for 8.5 months at 25% lower anti-seizure medication)
Initial data from first two pediatric patients showed improvements across multiple efficacy measures and clinical domains, with early evidence of developmental gains (patient one: improved hand function, grasp and gross motor coordination, gained visual reception and receptive language skills; patient two: gained ability to stand up from chair and walk up a stair, increase in seizure-free days)
IDMC approved Company’s request for early advancement to cohort two (high dose) in the REVEAL pediatric trial; dosing expected in Q3 2024 following IDMC review of initial safety data from the first high dose patient in the adolescent and adult trial
Company will host webcast today at 8:00 AM Eastern Time
https://ir.tayshagtx.com/news-relea...apies-announces-positive-clinical-data-across
- Forums
- ASX - By Stock
- NEU
- Competitors to Daybue
Competitors to Daybue, page-9
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B |
Open | High | Low | Value | Volume |
$15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1498 | $15.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.50 | 8296 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1498 | 15.450 |
1 | 319 | 15.420 |
1 | 33 | 15.400 |
2 | 6322 | 15.370 |
1 | 5004 | 15.350 |
Price($) | Vol. | No. |
---|---|---|
15.500 | 8296 | 2 |
15.510 | 2291 | 1 |
15.540 | 2291 | 1 |
15.560 | 3500 | 1 |
15.570 | 2291 | 1 |
Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online